If We Pull the Plug on Drug Rebates, Can We Finally Focus on Value?

Posted by Pratap Khedkar on Thu, Oct 18, 2018


As more healthcare stakeholders clamor for price transparency, prescription drug rebates’ days could be numbered. Whether the behind-the-scenes negotiation tool—which has been linked to a growing discrepancy between a drug’s list and net prices—will partially or completely disappear is up for debate, but one certainty at this point is that the price transparency knock rarely goes unanswered.

Read More